Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents (Q34660821)

3 August 2017

1 reference

title

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents (English)

1 reference

3 August 2017

main subject

angiogenesis inhibitor

1 reference

George D Hartman

1

1 reference

3 August 2017

Mark E Fraley

series ordinal

2

1 reference

3 August 2017

Mark T Bilodeau

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

737-745

1 reference

Angiogenesis and tumor metastasis

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Vascular endothelial growth factor, a potent and selective angiogenic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Molecular and biological properties of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

The role of VEGF and thrombospondins in skin angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.737

10.1517/13543784.11.6.737

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference